<SEC-DOCUMENT>0001193805-20-000259.txt : 20200224
<SEC-HEADER>0001193805-20-000259.hdr.sgml : 20200224
<ACCEPTANCE-DATETIME>20200224073027
ACCESSION NUMBER:		0001193805-20-000259
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20200221
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200224
DATE AS OF CHANGE:		20200224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		20642058

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e619399_8k-adma.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<U>February 21, 2020</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 18pt"><B>ADMA BIOLOGICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center">(Exact name of registrant as specified in its charter)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 30%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 30%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 30%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Delaware</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">001-36728</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">56-2590442</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">File Number)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center">465 State Route 17, Ramsey, New Jersey </TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">07446</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <U>(201) 478-5552</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">(Former name or former address, if changed since last report.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">o</FONT> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border: Black 1pt solid; text-align: center">Title of each class</TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Trading Symbol(s)</TD>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Common stock, par value $0.0001 per share</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">ADMA</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Nasdaq Global Market</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><B>Item 8.01</B></TD>
    <TD><B>Other Events.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 21, 2020, ADMA Biologics, Inc., a Delaware corporation
(the &ldquo;Company&rdquo;), announced that it has completed the sale of 3,525,000 shares of common stock, $0.0001 par value per
share (the &ldquo;Common Stock&rdquo;), pursuant to the exercise of the Underwriters&rsquo; (as defined below) option to purchase
shares of Common Stock (the &ldquo;Option Exercise&rdquo;) pursuant to Section 2 of the Underwriting Agreement entered into by
and among the Company and the underwriters, for which Morgan Stanley &amp; Co. LLC and Jefferies LLC acted as representatives (the
&ldquo;Underwriters&rdquo;). The Company received gross proceeds of approximately $12.3 million before deducting the underwriting
discounts and commissions and estimated fees and expenses payable by the Company in connection with the Option Exercise. Morgan
Stanley &amp; Co. LLC and Jefferies LLC acted as joint book-running managers for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Company&rsquo;s press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 96px"><B>Item 9.01</B></TD>
    <TD><B>Financial Statements and Exhibits.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 90%"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>5.1</TD>
    <TD><A HREF="e619399_ex5-1.htm" STYLE="-sec-extract: exhibit">Opinion of Morgan, Lewis &amp; Bockius LLP.</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>23.1</TD>
    <TD><A HREF="e619399_ex5-1.htm" STYLE="-sec-extract: exhibit">Consent of Morgan, Lewis &amp; Bockius LLP (included in Exhibit 5.1).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD><A HREF="e619399_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release of the Company, dated February 24, 2020.</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SIGNATURE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>February 24, 2020</TD>
    <TD COLSPAN="3">ADMA Biologics, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:&nbsp;&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">/s/ Brian Lenz</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;&nbsp;</TD>
    <TD STYLE="width: 30%">Brian Lenz</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Executive Vice President and Chief Financial Officer</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>e619399_ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="image002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 21, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ADMA Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">465 Route 17</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ramsey, NJ 07446</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>ADMA Biologics, Inc., Registration Statement on Form S-3 (File No.&nbsp;333-234107)</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acted as counsel for ADMA Biologics, Inc., a Delaware
corporation (the &ldquo;Company&rdquo;), in connection with the offering and sale by the Company of 3,525,000 shares (the &ldquo;Option
Shares&rdquo;) of common stock, $0.0001 par value per share, of the Company (the &ldquo;Common Stock&rdquo;) pursuant to the exercise
of the underwriters&rsquo; option pursuant to Section 2 of that certain Underwriting Agreement, dated February 6, 2020, by and
among the Company and Morgan Stanley &amp; Co. LLC and Jefferies LLC, as representatives of the several underwriters named therein
(the &ldquo;Underwriting Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with this opinion letter, we have examined the
Company&rsquo;s registration statement on Form&nbsp;S-3 (Registration No. 333-234107) (the &ldquo;Registration Statement&rdquo;)
filed by the Company with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), which was declared effective on October 15, 2019, the Prospectus Supplement, dated
February 6, 2020 (the &ldquo;Prospectus Supplement&rdquo;) and the accompanying base prospectus dated October 15, 2019 (the &ldquo;Base
Prospectus&rdquo;) and originals, or copies certified or otherwise identified to our satisfaction, of the Second Amended and Restated
Certificate of Incorporation, as amended, the Amended and Restated Bylaws of the Company, the Underwriting Agreement, and such
other documents, records and other instruments as we have deemed appropriate for purposes of the opinion set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have assumed the genuineness of all signatures, the legal
capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals
of all documents submitted to us as certified, facsimile or photostatic copies and the authenticity of the originals of all documents
submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon the foregoing, we are of the opinion that the Option
Shares, when issued and sold by the Company and delivered by the Company against receipt of the purchase price therefor, in the
manner contemplated by the Prospectus Supplement and the Underwriting Agreement will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our opinion is limited solely to the Delaware General Corporation
Law without regard to choice of law, to the extent that the same may apply to or govern the transactions contemplated by the Registration
Statement. We express no opinion as to the effect of events occurring, circumstances arising, or changes of law becoming effective
or occurring, after the date hereof on the matters addressed in this opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the use of this opinion as Exhibit 5.1
to the Registration Statement and to the reference to us under the caption &ldquo;Legal Matters&rdquo; in the Prospectus Supplement.
In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under
Section&nbsp;7 of the Securities Act or the rules or regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Morgan, Lewis &amp; Bockius LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="image003.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>e619399_ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADMA Biologics Announces Closing of Full
Exercise of Underwriters&rsquo; Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RAMSEY, NJ and BOCA RATON, FL, February 24, 2020</B> -- ADMA
Biologics, Inc. (Nasdaq: ADMA) (&ldquo;ADMA&rdquo;), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,
marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection
and others at risk for certain infectious diseases, today announced the closing of the issuance of an additional 3,525,000 shares
of its common stock at a public offering price of $3.50 per share. The shares were issued pursuant to the full exercise of the
underwriters&rsquo; overallotment option in connection with ADMA&rsquo;s previously announced underwritten public offering of 23,500,000
shares of its common stock. The gross proceeds from the exercise of the overallotment option were approximately $12.3 million,
bringing the total gross proceeds to ADMA from the offering to approximately $94.6 million, before deducting underwriting discounts
and commissions and other estimated offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ADMA intends to use the net proceeds from this offering (i)
for the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV; (ii) to support the ongoing commercial sales
of BIVIGAM and ASCENIV; (iii) to expand the manufacturing capacity of its Boca Facility, including supply chain functions, and
enhance the robustness of its supply chain oversight; (iv) to expand its plasma collection facility network; (v) for research and
development and business development opportunities; and (vi) for general corporate purposes and other capital expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morgan Stanley and Jefferies LLC acted as joint book-running
managers for the offering. Oppenheimer &amp; Co. Inc. acted as co-manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering was made only by means of a prospectus supplement
and accompanying prospectus forming part of a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-234107) previously
filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on October 4, 2019, and declared effective by the SEC on
October 15, 2019. The final prospectus supplement and the accompanying prospectus relating to the offering was filed with the SEC
and is available on the SEC&rsquo;s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying
prospectus relating to the offering may be obtained from Morgan Stanley &amp; Co. LLC, 180 Varick Street, 2nd Floor, New York,
NY 10014, Attention: Prospectus Department, or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022; by phone at (877) 821-7388; or by e-mail at: Prospectus_Department@Jefferies.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release shall not constitute an offer to sell or
the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About ADMA Biologics, Inc. (ADMA) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ADMA Biologics is an end-to-end commercial biopharmaceutical
company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient
patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three
United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and
the prevention of certain infectious diseases: BIVIGAM&reg; (immune globulin intravenous, human) for the treatment of primary humoral
immunodeficiency (PI); ASCENIV&trade; (immune globulin intravenous, human &ndash; slra 10% liquid) for the treatment of PI; and
NABI-HB&reg; (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA&rsquo;s mission
is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for
the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer
from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents:
9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains &ldquo;forward-looking statements&rdquo;
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (&ldquo;we,&rdquo;
&ldquo;our&rdquo; or the &ldquo;Company&rdquo;). Forward-looking statements include, without limitation, any statement that may
predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as &ldquo;estimate,&rdquo;
&ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;forecast,&rdquo; &ldquo;target,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo;
&ldquo;planning,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;will,&rdquo; &ldquo;is likely,&rdquo; &ldquo;will likely,&rdquo;
&ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;may,&rdquo; or, in each case, their negative, or words or
expressions of similar meaning. These forward-looking statements include statements about the offering and ADMA&rsquo;s intended
use of proceeds generated from the offering. Actual events or results may differ materially from those described in this document
due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance
that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by
applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions
to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors
that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or
implied by the forward-looking statements, including, but not limited to, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the public offering and the risks and uncertainties described in our
filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any
amendments thereto.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COMPANY CONTACT: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brian Lenz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President and Chief Financial Officer | 201-478-5552
|www.admabiologics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR RELATIONS CONTACT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sam Martin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director, Argot Partners | 212-600-1902 | sam@argotpartners.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  Z ,,# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[U_X*5_\
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MK9Z;GKW[!O[9:?&7XP?%_P"%7B"X6?7/!7B/4/L F.XWNF-<.H7!Z^43L/\
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M_P %[#\9_CKIGAGQ_P"'/#O@[1-61XH]6BOW*6TX&4$ID 54;!&[/!(KS?\
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M?0J^ ?V4]4\9_#NR\5:CXE\$^#]#U6>:WTZ;Q!JGV9]1:$@2F*-5=BJD@%B
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M*5O#.J,I!T[4B/0V\G^%?U 44?\ $8Y?] G_ )/_ /:#_P"('Q_Z#7_X+_\
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=TT2N[+5F>9YQBL?-2Q,KVV2T2]$%%%%?:'F'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  G -P# 2(  A$! Q$!_\0
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M2.U$R$K(8E+$[20IF*YR& ^Y?^"@?_! /]F+_@K7^U]\1-1^%'QBT[P)\8M
MOE7QYH^F0QZG;&\=0QFDMO,C:.5LD2/&Y0R!@RB0/7Y6?\%5_P#@EGX!_P""
M<'[7OP/^"?P_\87?Q%^(NJ207'B>[9$BVW5U>QQ6=LMNC/Y/RJS;69G(E5B<
M,H !]P?\'LWA'4['XK?LY^++VSGOO!\,&IZ?*H_U8N!-:RO&3V:2(<>HB;TK
M]'OVK/\ @J=^R]JO_!)WQ;XOB\=>!]2\$>(O!5UIVFZ!#>P&[NWFM&BCTX6@
M/F+*&81E"H\O!)P%)KZ(_;L_83^'?_!1?]G?5/AG\3-*?4="U!UN()[>3RKS
M2[I,^7<V\F#LE7<PZ$$,RL"K$'\F?AQ_P9(> M ^,*:AXC^-?B+Q!X)@E,BZ
M/#H4=G>W _ACDN1,R[?[Q2,%AG&PG( ,/_@QQ_Y)Y^T=_P!A'0/_ $5J%<-_
MP:U(I_X+G?M2,54L--UP D<C_B?V_0U^GW_!%O\ X(I:/_P1MT/XA66D^/\
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MMXK5X=.T^Z[73M(S27$RDDH6VA6PV&8*5** /UMHHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !6 3T# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]SOC-\?\
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M5F=B H]R:R/AO\7_  G\9-(DO_"'BCP[XJL87\N2YT?4H;Z%'_NEXF8 ^V:
M.BHHHH **** "BBB@ HHHH **** "BBB@#R+]JKX^>+?@W?^ ='\$>$O#OB_
MQ'X^UV71K:#7/$<VA6-J(["[O7E>>&RO')VVI4*(>2XRP KS#P__ ,%8/!>K
M_":YO+JVDT[QWI>A7FL:KHOV75+_ $C21:S7UO+)/JMG83QQVCS:;>"*=H@T
MH1,1;W6.O3_VJOV-_"7[8=_X!A\;Z3X=\2>'/!FNRZW<Z%KFBPZK8ZN6L+NT
M1'CFRBE&N1*&*/S$  "=PP/BE^PI8^/-*^*VGZ9J]IX<TWXD> [#P+:6=KI*
M^1H$-H-05)(T61%=-M\ (@(PHA #?-\KA:SYN_X6_P _7U0W9R5MK?CS?I'T
M^9T-C^W'\--0^/I^&4>MZ@?&"7YTIXO[!U'[!'>BQ&H?9#?F 6@G-H?.6(S!
MV16(4[3C+TC_ (*(_"WQ#X$O?$NGW?C6_P!$MKN*RM+FU\!:]-_PD$DGF%#I
M2+9%]5C*122>98"=!$AD+"/YJH:G^PK#K/C>[U6Y\1^9;WWQ!7QS+:_8"NY!
MH T<V>\2YY ,OFXXSMV?QUY7XN_X)4Z]\1OV;/!WPT\4^,OAAXQT?X4:A93^
M!XO$/PQ_M.Q%K;6D]D+?6K2743'J+&VG&);?["5FB60#&8Z2^"[^+W/O=N?_
M ,!NTEK>S=]DQ6NNUG]_O67G>R;>EKVL]7'T3P)_P4Z^'GCOXU:]X;B_MNU\
M.Z/X0L/&:^*[C0]3AT?['<1WDLIN;J2U6VLQ#':Y/GS*6=I8]HD@D4;FG?\
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M9VM'Z3\%OV%/!O@G3_#VJ^,M!\%>/?B/H6J:CKL?BRY\,P17-E?7]W)=7+V
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B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
